Gli inibitori della fosfodiesterasi-5 nella patologia cardiopolmonare: Dai rilievi sperimentali all'applicazione clinica

Translated title of the contribution: Clinical use of phosphodiesterases-5 inhibitors in cardiopulmonary diseases: From experimental evidence to clinical application

Marco Guazzi, Marco Vicenzi, Michele Samaja

Research output: Contribution to journalArticle

Abstract

Phosphodiesterases are a class of proteins that primarily modulate intracellular levels of cyclic nucleotides such as cGMP and cAMP. Phosphodiesterase-5 (PDE5) is mainly involved in the smooth muscle cell cGMP inactivation. Chemical inhibition of PDE5 has recently become a valid therapeutic option of nitric oxide pathway potentiation via cell cGMP availability. More specifically, PDE5 inhibition appears successful for the treatment of idiopathic pulmonary arterial hypertension. Additional intriguing therapeutic properties are a protective effect on the myocardium through antihypertrophic and antiapoptotic mechanisms and on vascular function by improving endothelial responsiveness and tolerance to myocardial ischemia-reperfusion injury. These effects imply a potential usefulness in the treatment of coronary artery disease and heart failure. Evidence currently available for considering PDE5 inhibition an additional therapeutic opportunity in cardiovascular disorders is provided.

Original languageItalian
Pages (from-to)725-737
Number of pages13
JournalGiornale Italiano di Cardiologia
Volume10
Issue number11-12
Publication statusPublished - 2009

Fingerprint

Type 5 Cyclic Nucleotide Phosphodiesterases
Phosphodiesterase 5 Inhibitors
Myocardial Reperfusion Injury
Cyclic Nucleotides
Phosphoric Diester Hydrolases
Reperfusion Injury
Smooth Muscle Myocytes
Myocardial Ischemia
Blood Vessels
Coronary Artery Disease
Myocardium
Nitric Oxide
Therapeutics
Heart Failure
Proteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Gli inibitori della fosfodiesterasi-5 nella patologia cardiopolmonare : Dai rilievi sperimentali all'applicazione clinica. / Guazzi, Marco; Vicenzi, Marco; Samaja, Michele.

In: Giornale Italiano di Cardiologia, Vol. 10, No. 11-12, 2009, p. 725-737.

Research output: Contribution to journalArticle

@article{9eaee1e2599c499eb9d1f481ad2a20f8,
title = "Gli inibitori della fosfodiesterasi-5 nella patologia cardiopolmonare: Dai rilievi sperimentali all'applicazione clinica",
abstract = "Phosphodiesterases are a class of proteins that primarily modulate intracellular levels of cyclic nucleotides such as cGMP and cAMP. Phosphodiesterase-5 (PDE5) is mainly involved in the smooth muscle cell cGMP inactivation. Chemical inhibition of PDE5 has recently become a valid therapeutic option of nitric oxide pathway potentiation via cell cGMP availability. More specifically, PDE5 inhibition appears successful for the treatment of idiopathic pulmonary arterial hypertension. Additional intriguing therapeutic properties are a protective effect on the myocardium through antihypertrophic and antiapoptotic mechanisms and on vascular function by improving endothelial responsiveness and tolerance to myocardial ischemia-reperfusion injury. These effects imply a potential usefulness in the treatment of coronary artery disease and heart failure. Evidence currently available for considering PDE5 inhibition an additional therapeutic opportunity in cardiovascular disorders is provided.",
keywords = "Heart failure, Pulmonary arterial hypertension",
author = "Marco Guazzi and Marco Vicenzi and Michele Samaja",
year = "2009",
language = "Italian",
volume = "10",
pages = "725--737",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "11-12",

}

TY - JOUR

T1 - Gli inibitori della fosfodiesterasi-5 nella patologia cardiopolmonare

T2 - Dai rilievi sperimentali all'applicazione clinica

AU - Guazzi, Marco

AU - Vicenzi, Marco

AU - Samaja, Michele

PY - 2009

Y1 - 2009

N2 - Phosphodiesterases are a class of proteins that primarily modulate intracellular levels of cyclic nucleotides such as cGMP and cAMP. Phosphodiesterase-5 (PDE5) is mainly involved in the smooth muscle cell cGMP inactivation. Chemical inhibition of PDE5 has recently become a valid therapeutic option of nitric oxide pathway potentiation via cell cGMP availability. More specifically, PDE5 inhibition appears successful for the treatment of idiopathic pulmonary arterial hypertension. Additional intriguing therapeutic properties are a protective effect on the myocardium through antihypertrophic and antiapoptotic mechanisms and on vascular function by improving endothelial responsiveness and tolerance to myocardial ischemia-reperfusion injury. These effects imply a potential usefulness in the treatment of coronary artery disease and heart failure. Evidence currently available for considering PDE5 inhibition an additional therapeutic opportunity in cardiovascular disorders is provided.

AB - Phosphodiesterases are a class of proteins that primarily modulate intracellular levels of cyclic nucleotides such as cGMP and cAMP. Phosphodiesterase-5 (PDE5) is mainly involved in the smooth muscle cell cGMP inactivation. Chemical inhibition of PDE5 has recently become a valid therapeutic option of nitric oxide pathway potentiation via cell cGMP availability. More specifically, PDE5 inhibition appears successful for the treatment of idiopathic pulmonary arterial hypertension. Additional intriguing therapeutic properties are a protective effect on the myocardium through antihypertrophic and antiapoptotic mechanisms and on vascular function by improving endothelial responsiveness and tolerance to myocardial ischemia-reperfusion injury. These effects imply a potential usefulness in the treatment of coronary artery disease and heart failure. Evidence currently available for considering PDE5 inhibition an additional therapeutic opportunity in cardiovascular disorders is provided.

KW - Heart failure

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=72949091311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949091311&partnerID=8YFLogxK

M3 - Articolo

C2 - 20101899

AN - SCOPUS:72949091311

VL - 10

SP - 725

EP - 737

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 11-12

ER -